Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Viking Therapeutics, Inc.VKTX · Entity 4067 | Director | January 02, 2026 | January 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Viking Therapeutics, Inc.
Report date January 02, 2026 · Filed January 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.00001 per shareSEC Table I · non-derivative | Direct | 51,115 |
Reported balance
After 2026-01-02 transaction · row 1
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 3,150 · Balance 51,115 F1: Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2024 Equity Incentive Plan. All shares subject to the RSU shall vest on the one year anniversary of the grant date of the award. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.42 · Expires 2036-01-02 | Direct | 20,400 |
Reported balance
After 2026-01-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-02 · Grant · Acquired 20,400 · Balance 20,400 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2024 Equity Incentive Plan. All shares subject to the RSU shall vest on the one year anniversary of the grant date of the award.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2026 Filed Jan 5, 2026 20:26 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantStock Option (Right to Buy) · Derivative | 20,400 | $0.00 Strike: $35.42 | $0.00 |
DisclosureSEC source: 0001193125-26-003111 · ownership.xml · derivative · entry 2 MACARTNEY LAWSON · CIK 0001606831 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,400 Underlying: Common Stock · 20,400 shares Expires 2036-01-02 Read SEC document |
| January 02, 2026 Filed Jan 5, 2026 20:26 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantCommon Stock, par value $0.00001 per share | 3,150 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-003111 · ownership.xml · nonDerivative · entry 1 MACARTNEY LAWSON · CIK 0001606831 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,115 F1 · shares: Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2024 Equity Incentive Plan. All shares subject to the RSU shall vest on the one year anniversary of the grant date of the award. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 20:14 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantStock Option (Right to Buy) · Derivative | 18,800 | $0.00 Strike: $41.12 | $0.00 |
DisclosureSEC source: 0000950170-25-002484 · ownership.xml · derivative · entry 1 MACARTNEY LAWSON · CIK 0001606831 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,800 Underlying: Common Stock · 18,800 shares Expires 2035-01-02 Read SEC document |
| November 08, 2024 Filed Nov 8, 2024 18:22 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $5.80 | $0.00 |
DisclosureSEC source: 0000950170-24-124296 · ownership.xml · derivative · entry 3 MACARTNEY LAWSON · CIK 0001606831 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 2,000 shares Expires 2031-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 08, 2024 Filed Nov 8, 2024 18:22 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 2,000 | $68.67 | $137,333.40 |
DisclosureSEC source: 0000950170-24-124296 · ownership.xml · nonDerivative · entry 2 MACARTNEY LAWSON · CIK 0001606831 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,965 Read SEC document |
| November 08, 2024 Filed Nov 8, 2024 18:22 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionCommon Stock, par value $0.00001 per share | 2,000 | $5.80 | $11,600.00 |
DisclosureSEC source: 0000950170-24-124296 · ownership.xml · nonDerivative · entry 1 MACARTNEY LAWSON · CIK 0001606831 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,965 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:24 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantStock Option (Right to Buy) · Derivative | 32,000 | $0.00 Strike: $18.28 | $0.00 |
DisclosureSEC source: 0001209191-24-000922 · doc4.xml · derivative · entry 1 MACARTNEY LAWSON · CIK 0001606831 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 32,000 shares Expires 2034-01-02 Read SEC document |
| May 16, 2023 Filed May 18, 2023 18:30 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $1.19 | $0.00 |
DisclosureSEC source: 0001209191-23-030794 · doc4.xml · derivative · entry 3 MACARTNEY LAWSON · CIK 0001606831 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,000 shares Expires 2027-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| May 16, 2023 Filed May 18, 2023 18:30 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 16,000 | $24.00 | $384,000.00 |
DisclosureSEC source: 0001209191-23-030794 · doc4.xml · nonDerivative · entry 2 MACARTNEY LAWSON · CIK 0001606831 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,965 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| May 16, 2023 Filed May 18, 2023 18:30 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionCommon Stock, par value $0.00001 per share | 16,000 | $1.19 | $19,040.00 |
DisclosureSEC source: 0001209191-23-030794 · doc4.xml · nonDerivative · entry 1 MACARTNEY LAWSON · CIK 0001606831 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,965 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| April 24, 2023 Filed Apr 24, 2023 19:31 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $3.33 | $0.00 |
DisclosureSEC source: 0001209191-23-025473 · doc4.xml · derivative · entry 3 MACARTNEY LAWSON · CIK 0001606831 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,000 shares Expires 2026-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| April 24, 2023 Filed Apr 24, 2023 19:31 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 16,000 | $22.00 | $352,060.80 |
DisclosureSEC source: 0001209191-23-025473 · doc4.xml · nonDerivative · entry 2 MACARTNEY LAWSON · CIK 0001606831 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,965 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| April 24, 2023 Filed Apr 24, 2023 19:31 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionCommon Stock, par value $0.00001 per share | 16,000 | $3.33 | $53,280.00 |
DisclosureSEC source: 0001209191-23-025473 · doc4.xml · nonDerivative · entry 1 MACARTNEY LAWSON · CIK 0001606831 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,965 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| April 17, 2023 Filed Apr 18, 2023 19:10 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,786 | $0.00 Strike: $8.00 | $0.00 |
DisclosureSEC source: 0001209191-23-024725 · doc4.xml · derivative · entry 3 MACARTNEY LAWSON · CIK 0001606831 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,786 shares Expires 2025-04-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person. F2 · derivative.exercise_date: 100% of the shares subject to the option vested on May 26, 2016, the date of the Issuer's first Annual Meeting of Stockholders following the date of grant. Read SEC document |
| April 17, 2023 Filed Apr 18, 2023 19:10 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 20,786 | $20.00 | $415,720.00 |
DisclosureSEC source: 0001209191-23-024725 · doc4.xml · nonDerivative · entry 2 MACARTNEY LAWSON · CIK 0001606831 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,965 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| April 17, 2023 Filed Apr 18, 2023 19:10 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionCommon Stock, par value $0.00001 per share | 20,786 | $8.00 | $166,288.00 |
DisclosureSEC source: 0001209191-23-024725 · doc4.xml · nonDerivative · entry 1 MACARTNEY LAWSON · CIK 0001606831 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,751 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 18:11 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantStock Option (Right to Buy) · Derivative | 22,000 | $0.00 Strike: $8.52 | $0.00 |
DisclosureSEC source: 0001209191-23-001311 · doc4.xml · derivative · entry 1 MACARTNEY LAWSON · CIK 0001606831 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2033-01-03 Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 19:09 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantStock Option (Right to Buy) · Derivative | 22,000 | $0.00 Strike: $4.88 | $0.00 |
DisclosureSEC source: 0001209191-22-001981 · doc4.xml · derivative · entry 1 MACARTNEY LAWSON · CIK 0001606831 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2032-01-03 Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 16:41 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantStock Option (Right to Buy) · Derivative | 22,000 | $0.00 Strike: $5.80 | $0.00 |
DisclosureSEC source: 0001209191-21-002135 · doc4.xml · derivative · entry 1 MACARTNEY LAWSON · CIK 0001606831 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2031-01-04 Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 19:57 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantStock Option (Right to Buy) · Derivative | 22,000 | $0.00 Strike: $7.95 | $0.00 |
DisclosureSEC source: 0001209191-20-001420 · doc4.xml · derivative · entry 1 MACARTNEY LAWSON · CIK 0001606831 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2030-01-02 Read SEC document |
| January 02, 2019 Filed Jan 3, 2019 20:22 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantStock Option (Right to Buy) · Derivative | 22,000 | $0.00 Strike: $8.32 | $0.00 |
DisclosureSEC source: 0001209191-19-001561 · doc4.xml · derivative · entry 1 MACARTNEY LAWSON · CIK 0001606831 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2029-01-02 Read SEC document |
| May 29, 2018 Filed May 31, 2018 18:57 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | PurchaseCommon Stock, par value $0.00001 per share | 47,965 | $5.22 | $250,329.34 |
DisclosureSEC source: 0001209191-18-034482 · doc4.xml · nonDerivative · entry 1 MACARTNEY LAWSON · CIK 0001606831 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,965 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.1417 to $5.2412, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 16:16 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $4.48 | $0.00 |
DisclosureSEC source: 0001209191-18-000840 · doc4.xml · derivative · entry 1 MACARTNEY LAWSON · CIK 0001606831 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2028-01-02 Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 19:15 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $1.19 | $0.00 |
DisclosureSEC source: 0001209191-17-002379 · doc4.xml · derivative · entry 1 MACARTNEY LAWSON · CIK 0001606831 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2027-01-03 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.